VCYT
Veracyte, Inc.
$56.97
-2.33
(-3.93%)
Mkt Cap
4.55B
Volume
757,211
52W Range
22.61-60.91
Sector
Healthcare
Beta
1.93
EPS (TTM)
1.11
P/E Ratio
51.44
Revenue (TTM)
541.74M
Rev Growth (5Y)
+34.5%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$49.88
Overvalued
weak signal
14.2% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517.14M | 445.76M | 361.05M | 296.54M | 219.51M | 117.48M | 120.37M | 92.01M | 71.95M | 65.08M | 49.50M | 38.19M |
| Net Income | 66.35M | 24.14M | (74.40M) | (36.56M) | (75.56M) | (34.91M) | (12.60M) | (23.00M) | (31.00M) | (31.36M) | (33.70M) | (29.37M) |
| EPS | 0.84 | 0.32 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 | -1.30 | -1.36 |
| Free Cash Flow | 126.63M | 63.81M | 34.26M | (1.01M) | (37.00M) | (12.55M) | (5.99M) | (15.39M) | (25.67M) | (32.19M) | (33.13M) | (29.66M) |
| FCF / Share | 1.61 | 0.83 | 0.47 | -0.01 | -0.54 | -0.24 | -0.13 | -0.42 | -0.76 | -1.12 | -1.28 | -1.37 |
| Operating CF | 136.31M | 75.10M | 44.22M | 7.54M | (31.62M) | (9.71M) | (3.23M) | (13.52M) | (23.91M) | (27.98M) | (26.96M) | (27.63M) |
| Total Assets | 1.41B | 1.30B | 1.11B | 1.16B | 1.19B | 457.16M | 275.21M | 120.64M | 78.67M | 101.03M | 75.28M | 64.84M |
| Total Debt | 39.65M | 50.74M | 12.63M | 14.72M | 18.85M | 12.32M | 13.61M | 25.28M | 25.25M | 25.52M | 5.03M | 4.92M |
| Cash & Equiv | 362.58M | 239.09M | 216.45M | 154.25M | 173.20M | 349.36M | 159.32M | 78.00M | 33.89M | 59.22M | 39.08M | 35.01M |
| Book Value | 1.31B | 1.18B | 1.04B | 1.08B | 1.10B | 421.23M | 239.46M | 79.75M | 37.23M | 59.58M | 51.25M | 41.37M |
| Return on Equity | 0.05 | 0.02 | -0.07 | -0.03 | -0.07 | -0.08 | -0.05 | -0.29 | -0.83 | -0.53 | -0.66 | -0.71 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.07M | 140.64M | 131.87M | 130.16M | 114.47M | 118.63M | 115.86M | 114.43M | 96.84M | 98.20M | 90.11M | 90.32M |
| Net Income | 28.71M | 41.15M | 19.14M | (980,000) | 7.05M | 5.11M | 15.15M | 5.73M | (1.86M) | (28.29M) | (29.62M) | (8.40M) |
| EPS | 0.36 | 0.52 | 0.24 | -0.01 | 0.09 | 0.07 | 0.20 | 0.07 | -0.02 | -0.39 | -0.41 | -0.12 |
| Free Cash Flow | 32.25M | 48.27M | 41.97M | 32.32M | 3.54M | 20.38M | 27.72M | 26.80M | (11.10M) | 13.05M | 11.37M | 13.00M |
| FCF / Share | 0.41 | 0.61 | 0.53 | 0.41 | 0.05 | 0.26 | 0.36 | 0.35 | -0.15 | 0.18 | 0.16 | 0.18 |
| Operating CF | 35.22M | 52.58M | 44.76M | 33.60M | 5.36M | 24.52M | 29.96M | 29.57M | (8.97M) | 15.55M | 14.17M | 16.67M |
| Total Assets | 1.44B | 1.41B | 1.37B | 1.34B | 1.32B | 1.30B | 1.28B | 1.23B | 1.20B | 1.11B | 1.12B | 1.16B |
| Total Debt | 39.33M | 39.65M | 40.45M | 50.65M | 50.50M | 50.74M | 19.69M | 20.74M | 14.04M | 12.63M | 13.73M | 14.86M |
| Cash & Equiv | 263.14M | 362.58M | 315.57M | 219.50M | 186.12M | 239.09M | 274.08M | 235.91M | 209.19M | 216.45M | 202.46M | 191.14M |
| Book Value | 1.34B | 1.31B | 1.26B | 1.22B | 1.19B | 1.18B | 1.18B | 1.13B | 1.12B | 1.04B | 1.05B | 1.08B |
| Return on Equity | 0.02 | 0.03 | 0.02 | -0.00 | 0.01 | 0.00 | 0.01 | 0.01 | -0.00 | -0.03 | -0.03 | -0.01 |
VCYT News
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Here's Why Veracyte (VCYT) is a Strong Growth Stock
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript